Clinical Trials

The Eleanor and Lou Gehrig ALS Center at Columbia University is a leading ALS clinical research center, offering ALS patients throughout the New York area the opportunity to participate in the testing of the most promising candidate ALS therapies.

The development of novel therapies for ALS is a primary focus of ALS research efforts at Columbia. The Experimental Therapeutics Group is supported by Matthew Harms, MD, who leads the Columbia ALS Precision Medicine Initiative, and Neil Shneider, MD, whose interests focuses on the pre-clinical development of novel ALS therapies.

If you are interested in participating in a study, please call 212-305-6788, or email alsresearch@cumc.columbia.edu.